Safety study of GCC2005 for NK and T-cell cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called GCC2005 for people with certain types of NK or T-cell cancers that have come back or not responded to at least two previous treatments. The goal is to see if it is safe and if it can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of NK or T-cell cancer that tests positive for CD5.
- Your cancer has come back or not responded to at least two standard chemotherapy treatments, and your doctor says no other options are available.
- You have at least one tumor that can be measured on a scan (at least 1.5 cm for nodes or 1.0 cm for other areas).
- You are well enough to be up and about (ECOG score of 0, 1, or 2).
- You have not had a previous CAR-T or CAR-NK treatment, or an allogeneic organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called MB-105 for people with a type of T-cell lymphoma that has come back or not responded to other treatments. MB-105 is designed to target and attack cancer cells that have a specific marker called CD5 on their surface.
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
This trial tests a new drug, GNC-035, for people with non-Hodgkin's lymphoma that has come back (relapsed) or stopped responding to standard treatments (refractory). The goal is to see if GNC-035 can help when other options haven't worked.
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
This trial tests an investigational drug called ELA026 for people with T-cell or NK-cell cancers that came back or didn't get better after prior treatment. The goal is to see if ELA026 can help shrink the cancer or slow its growth.
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
Hear when a new Lymphoma, T-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.